EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report)'s stock price shot up 9.2% on Tuesday . The stock traded as high as $8.25 and last traded at $8.10. 566,794 shares traded hands during mid-day trading, a decline of 32% from the average session volume of 827,576 shares. The stock had previously closed at $7.42.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on the stock. Mizuho decreased their target price on shares of EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a research note on Friday, May 16th. Wall Street Zen raised shares of EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. Chardan Capital cut their target price on shares of EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, May 29th. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $25.38.
Read Our Latest Stock Report on EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Price Performance
The company has a market capitalization of $562.19 million, a P/E ratio of -4.09 and a beta of 1.58. The business has a 50-day moving average of $5.98 and a 200-day moving average of $6.93.
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.65). The company had revenue of $24.50 million during the quarter, compared to the consensus estimate of $8.84 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. Sell-side analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.
Institutional Trading of EyePoint Pharmaceuticals
A number of institutional investors have recently bought and sold shares of EYPT. California State Teachers Retirement System lifted its position in shares of EyePoint Pharmaceuticals by 3.8% during the fourth quarter. California State Teachers Retirement System now owns 48,614 shares of the company's stock worth $362,000 after purchasing an additional 1,797 shares during the last quarter. Arizona State Retirement System lifted its position in shares of EyePoint Pharmaceuticals by 12.7% during the first quarter. Arizona State Retirement System now owns 16,600 shares of the company's stock worth $90,000 after purchasing an additional 1,877 shares during the last quarter. Legal & General Group Plc lifted its position in shares of EyePoint Pharmaceuticals by 4.4% during the fourth quarter. Legal & General Group Plc now owns 46,263 shares of the company's stock worth $345,000 after purchasing an additional 1,932 shares during the last quarter. Summit Investment Advisors Inc. lifted its position in shares of EyePoint Pharmaceuticals by 39.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock worth $51,000 after purchasing an additional 1,940 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of EyePoint Pharmaceuticals by 16.1% during the fourth quarter. Invesco Ltd. now owns 15,657 shares of the company's stock worth $117,000 after purchasing an additional 2,177 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors.
About EyePoint Pharmaceuticals
(
Get Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Recommended Stories
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
